Related Experiment Video
Updated: Jun 8, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Dronedarone. atrial fibrillation: too many questions about long-term adverse effects
Insights
Dronedarone is less effective than amiodarone for atrial fibrillation and has potential risks. Betablockers or amiodarone are preferred for managing atrial fibrillation due to better-documented safety profiles.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation management often starts with betablockers.
- Amiodarone is a last resort due to adverse effects.
- Dronedarone, similar to amiodarone, is a newer option.
Purpose of the Study:
- To evaluate dronedarone's efficacy and safety compared to amiodarone and placebo.
- To assess dronedarone's role in atrial fibrillation and heart failure treatment.
Main Methods:
- Double-blind trial comparing dronedarone and amiodarone in 504 patients.
- Two placebo-controlled trials in heart failure patients.
- Analysis of adverse effects including mortality, gastrointestinal, thyroid, neurological, and renal issues.
Main Results:
- Dronedarone showed a significantly higher failure rate (75.1%) versus amiodarone (58.8%).
- Conflicting results in heart failure trials; increased mortality in one, no significant difference in another.
- Dronedarone has arrhythmogenic effects and other adverse events like GI issues, but fewer thyroid and neurological issues than amiodarone.
Conclusions:
- Dronedarone is less effective than amiodarone in the short term.
- Betablockers or amiodarone are recommended over dronedarone due to better-documented safety and efficacy.
- Long-term adverse effects of dronedarone, particularly pulmonary fibrosis, require further investigation.
Abstract:
In patients with atrial fibrillation, a betablocker is generally used initially to prevent recurrence or to slow the heart rate. Amiodarone is a last resort, mainly because of its numerous adverse effects. Dronedarone, chemically similar to amiodarone,was recently authorised for this indication in the European Union. In a double-blind trial versus amiodarone in 504 patients, the failure rate was significantly higher with dronedarone (75.1% versus 58.8%). Two placebo-controlled trials in heart failure patients yielded conflicting results. Dronedarone was associated with a statistically significant increase in mortality in a trial in 627 symptomatic patients free of arrhythmias. However, there was no statistically significant difference in a trial including 4630 patients with atrial fibrillation and a lower risk of cardiovascular events. There are no comparative trials versus other antiarrhythmic drugs or heart-rate-lowering agents, including betablockers and calcium channel blockers. Like other antiarrhythmic drugs, dronedarone also has arrhythmogenic effects, including bradycardia and QT prolongation. Other adverse effects include diarrhoea, nausea and vomiting, and cutaneous disorders. Transient elevation of creatinine levels is also frequent, and cases of renal failure have been reported. In the trial versus amiodarone, dronedarone had a different pattern of short-term adverse effects, including more gastrointestinal disorders but less frequent thyroid disorders, neurological disorders, hypersensitivity reactions, hypertension, and QT prolongation. Little is known of potential long-term adverse effects, especially pulmonary fibrosis. In practice, dronedarone is better tolerated but less effective than amiodarone in the short term.When antiarrhythmic drug therapy is needed, it is better to continue to use a betablocker or, as a last resort, amiodarone, a drug with better-documented adverse effects, especially during long-term treatment.
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

